Sinphar Pharmaceutical Co.,Ltd. (1734.TW)
TWD 29.1
(0.0%)
TWD 29.1
(0.0%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 2.24 TWD | 128.57% |
| 2022 | 0.98 TWD | 180.33% |
| 2021 | -1.22 TWD | -18.45% |
| 2020 | -1.03 TWD | -17.05% |
| 2019 | -0.88 TWD | -1779.39% |
| 2018 | 0.05 TWD | -76.18% |
| 2017 | 0.22 TWD | 120.0% |
| 2016 | 0.10 TWD | 25.0% |
| 2015 | 0.08 TWD | -91.75% |
| 2014 | 0.97 TWD | -45.81% |
| 2013 | 1.79 TWD | 141.89% |
| 2012 | 0.74 TWD | 51.02% |
| 2011 | 0.49 TWD | -36.36% |
| 2010 | 0.77 TWD | -21.43% |
| 2009 | 0.98 TWD | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | 0.39 TWD | -45.45% |
| 2024 Q1 | 0.66 TWD | 0.0% |
| 2023 FY | - TWD | 128.57% |
| 2023 Q1 | 0.48 TWD | 500.0% |
| 2023 Q2 | 0.65 TWD | 35.42% |
| 2023 Q3 | 0.45 TWD | -30.77% |
| 2023 Q4 | 0.66 TWD | 46.67% |
| 2022 Q3 | 0.41 TWD | -21.15% |
| 2022 Q1 | 0.27 TWD | 398.01% |
| 2022 FY | - TWD | 180.33% |
| 2022 Q4 | -0.12 TWD | -129.27% |
| 2022 Q2 | 0.52 TWD | 92.59% |
| 2021 Q4 | -0.09 TWD | 54.7% |
| 2021 Q3 | -0.20 TWD | -766.67% |
| 2021 FY | - TWD | -18.45% |
| 2021 Q1 | 0.03 TWD | 109.09% |
| 2021 Q2 | 0.03 TWD | 0.0% |
| 2020 Q4 | -0.33 TWD | -450.0% |
| 2020 Q1 | 0.16 TWD | -20.0% |
| 2020 Q2 | 0.05 TWD | -68.75% |
| 2020 FY | - TWD | -17.05% |
| 2020 Q3 | -0.06 TWD | -220.0% |
| 2019 Q4 | 0.20 TWD | 429.49% |
| 2019 Q3 | -0.06 TWD | 59.53% |
| 2019 FY | - TWD | -1779.39% |
| 2019 Q1 | 0.09 TWD | 85.95% |
| 2019 Q2 | -0.15 TWD | -266.67% |
| 2018 FY | - TWD | -76.18% |
| 2018 Q2 | -0.01 TWD | -110.0% |
| 2018 Q1 | 0.10 TWD | -23.08% |
| 2018 Q4 | 0.05 TWD | 153.78% |
| 2018 Q3 | -0.09 TWD | -800.0% |
| 2017 Q1 | -0.05 TWD | -119.48% |
| 2017 Q4 | 0.13 TWD | 62.5% |
| 2017 Q3 | 0.08 TWD | 33.33% |
| 2017 FY | - TWD | 120.0% |
| 2017 Q2 | 0.06 TWD | 214.07% |
| 2016 Q3 | -0.04 TWD | -170.27% |
| 2016 FY | - TWD | 25.0% |
| 2016 Q4 | 0.27 TWD | 775.0% |
| 2016 Q2 | -0.01 TWD | 85.2% |
| 2016 Q1 | -0.10 TWD | -126.32% |
| 2015 FY | - TWD | -91.75% |
| 2015 Q1 | -0.16 TWD | -148.48% |
| 2015 Q2 | -0.06 TWD | 63.81% |
| 2015 Q4 | 0.38 TWD | 480.0% |
| 2015 Q3 | -0.10 TWD | -72.71% |
| 2014 Q4 | 0.33 TWD | 353.85% |
| 2014 Q2 | 0.41 TWD | 10.81% |
| 2014 Q1 | 0.37 TWD | 85.0% |
| 2014 FY | - TWD | -45.81% |
| 2014 Q3 | -0.13 TWD | -131.71% |
| 2013 Q1 | 0.72 TWD | 1722.78% |
| 2013 Q3 | 0.53 TWD | 51.43% |
| 2013 Q4 | 0.20 TWD | -62.26% |
| 2013 FY | - TWD | 141.89% |
| 2013 Q2 | 0.35 TWD | -51.39% |
| 2012 Q4 | 0.04 TWD | -88.38% |
| 2012 Q3 | 0.34 TWD | 54.55% |
| 2012 FY | - TWD | 51.02% |
| 2012 Q2 | 0.22 TWD | 69.23% |
| 2012 Q1 | 0.13 TWD | 42.54% |
| 2011 Q2 | 0.14 TWD | -12.5% |
| 2011 Q1 | 0.16 TWD | 0.0% |
| 2011 Q3 | 0.08 TWD | -41.86% |
| 2011 Q4 | 0.09 TWD | 12.04% |
| 2011 FY | - TWD | -36.36% |
| 2010 Q3 | 0.09 TWD | -67.61% |
| 2010 FY | - TWD | -21.43% |
| 2010 Q1 | 0.24 TWD | 0.0% |
| 2010 Q4 | 0.16 TWD | 76.41% |
| 2010 Q2 | 0.28 TWD | 16.67% |
| 2009 FY | - TWD | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Apex Biotechnology Corp. | 1.16 TWD | -93.103% |
| Panion & Bf Biotech Inc. | 0.90 TWD | -148.889% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 3.42 TWD | 34.503% |
| GenMont Biotech Incorporation | 0.38 TWD | -489.474% |
| Abnova (Taiwan) Corporation | 0.72 TWD | -211.111% |
| Adimmune Corporation | -1.52 TWD | 247.368% |
| Tanvex BioPharma, Inc. | -16.42 TWD | 113.642% |
| Polaris Group | -2.12 TWD | 205.66% |
| Energenesis Biomedical CO.,LTD. | -3.62 TWD | 161.878% |
| UnicoCell Biomed Co., Ltd. | -1.56 TWD | 243.59% |
| PELL Bio-Med Technology Co. Ltd. | -8.62 TWD | 125.986% |